NCT06680050
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06680050
Title Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL)
Acronym AUSTRAL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Mario Negri Institute for Pharmacological Research
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | CHE

Facility Status City State Zip Country Details
ASST degli Spedali Civili di Brescia NOT_YET_RECRUITING Brescia Italy Details
Azienda Ospedaliero Universitaria Careggi RECRUITING Florence Italy Details
IRCCS Ospedale Policlinico San Martino, Genova RECRUITING Genova Italy Details
ASST Grande Ospedale Metropolitano Niguarda RECRUITING Milan Italy Details
Fondazione IRCCS Istituto Nazionale dei Tumori RECRUITING Milan Italy Details
Azienda ospedaliera di Padova NOT_YET_RECRUITING Padua Italy Details
Azienda Ospedaliero - Universitaria di Parma NOT_YET_RECRUITING Parma Italy Details
University Hospital of Geneva NOT_YET_RECRUITING Geneva Switzerland Details
University Hospital Zurich NOT_YET_RECRUITING Zurich Switzerland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field